Advancing Immunotherapy: Unveiling Biomarkers and Mechanisms in the Tumor-Immune Nexus
Recent developments have highlighted the potential of immunotherapy in providing long-lasting responses across a range of cancer types, underscoring the need to study the interaction between cancer cells and the immune system. Specifically, immune checkpoint inhibitors have become a mainstay of cancer treatment, improving prognoses for patients. The variety of tumor-immune interactions presents serious difficulties, though, as a sizeable portion of patients need to react to these therapies. This emphasizes how crucial it is to comprehend the underlying cellular and molecular mechanisms of these interactions to utilize immunotherapy fully.In order to better understand the intricate world of tumor-immune interactions, this research topic will concentrate on finding and applying cutting-edge biomarkers and processes that can predict and improve immunotherapy's effectiveness. Given the immune system's critical role in preventing and treating cancer, a more detailed understanding of these interactions may result in more individualized and successful treatment plans. Recent developments in single-cell RNA sequencing, mass cytometry, and next-generation sequencing have created new opportunities for analyzing the intricacy of the tumor microenvironment and immune evasion tactics. This compilation aims to combine state-of-the-art studies that use these technologies to find novel biomarkers, comprehend resistance mechanisms, and pinpoint possible targets for treatment within the immunological context of malignancies. This topic aims to advance the field towards more responsive and predictive immunotherapy treatments by encouraging innovation and filling knowledge gaps.
Guest editors:
Nan Zhang - Huazhong University of Science and Technology College of Life Science and Technology, Wuhan, China.Hao Zhang - The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Manuscript submission information:
Manuscript Submission Deadline: 1st September 2025
The journal’s submission platform (https://www.editorialmanager.com/yphrs/default.aspx) is now available for receiving submissions to this Special Issue. Please refer to the Guide for Authors to prepare your manuscript, and select the article type of “VSI:Biomarkers and Mechanisms in Immunotherapy” when submitting your manuscript online. Both the Guide for Authors and the submission portal could be found on the Journal Homepage here: https://www.sciencedirect.com/journal/pharmacological-research
Keywords:
Immunotherapy, Biomarker, Mechanism, Targets
Pharmacological Research的CAR指数
2023年3月份科睿唯安官方一次性踢除35本SCI期刊，多数涉及学术诚信问题，让我们意识到学术期刊的“被踢”指数，也很重要。目前，对于期刊的“被踢”指数，这里介绍一下：CAR指数（关于CAR的详细介绍，请关注：www.jcarindex.com），这是一种评价期刊学术诚信风险的指数，指数越高代表可能的风险越大。从数据看，Pharmacological Research不管是2022年度，还是2023年度的CAR指数，都是比较低的。当然，CAR指数仅供参考，期刊风险情况，需以科睿唯安或中科院预警等官方为准！
让推送更美好~
